Canadian antibody therapeutics development company AbCellera Biologics Inc. closed its Series A financing.
The round of funding was led by DCVC Bio, a Silicon Valley venture capital fund.
AbCellera will use the $10 million financing to accelerate the growth of its therapeutic antibody discovery business, including investments to build capacity and integration of advanced technological capabilities spanning computation, protein engineering, and immune repertoire profiling.
With this financing, AbCellera will double-down on its partnership business that has had profitable, triple-digit growth over the past 3 years.